Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy
- PMID: 16123586
- DOI: 10.4161/cc.4.9.2031
Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy
Abstract
Poly(ADP-ribose) polymerase (PARP-1) binds to DNA breaks to facilitate DNA repair. However, the role of PARP-1 in DNA repair appears to not be critical since PARP-1 knockout mice are viable, fertile and do not develop early onset tumors. Cells isolated from these mice show an increased level of homologous recombination. There is an intricate link between homologous recombination and PARP-1 and a possible role for PARP-1 in DNA double-strand break repair. Although PARP-1 appears not to be required for homologous recombination itself, it regulates the process through its involvement in the repair of DNA single-strand breaks (SSBs). SSBs persisting into the S phase of the cell cycle collapse replication forks, triggering homologous recombination for replication restart. We discuss the recent discoveries on the use of PARP-1 inhibitors as a targeted cancer therapy for recombination deficient cancers, such as BRCA2 tumors.
Similar articles
-
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.Nature. 2005 Apr 14;434(7035):913-7. doi: 10.1038/nature03443. Nature. 2005. PMID: 15829966
-
Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells.Cancer Res. 2010 Jul 1;70(13):5389-98. doi: 10.1158/0008-5472.CAN-09-4716. Epub 2010 Jun 15. Cancer Res. 2010. PMID: 20551068
-
Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair.Nucleic Acids Res. 2006 Mar 23;34(6):1685-91. doi: 10.1093/nar/gkl108. Print 2006. Nucleic Acids Res. 2006. PMID: 16556909 Free PMC article.
-
[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].Bull Cancer. 2015 Oct;102(10):863-73. doi: 10.1016/j.bulcan.2015.07.012. Epub 2015 Sep 15. Bull Cancer. 2015. PMID: 26384693 Review. French.
-
[Cancer therapy by PARP inhibitors].Nihon Rinsho. 2015 Aug;73(8):1330-5. Nihon Rinsho. 2015. PMID: 26281686 Review. Japanese.
Cited by
-
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.Br J Cancer. 2016 Nov 8;115(10):1157-1173. doi: 10.1038/bjc.2016.311. Epub 2016 Oct 13. Br J Cancer. 2016. PMID: 27736844 Free PMC article. Review.
-
Ubiquitylation in DNA double-strand break repair.DNA Repair (Amst). 2021 Jul;103:103129. doi: 10.1016/j.dnarep.2021.103129. Epub 2021 May 7. DNA Repair (Amst). 2021. PMID: 33990032 Free PMC article.
-
Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib.Clin Cancer Res. 2017 Apr 15;23(8):2050-2060. doi: 10.1158/1078-0432.CCR-16-0564. Epub 2016 Oct 4. Clin Cancer Res. 2017. PMID: 27702817 Free PMC article.
-
Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers.Curr Oncol Rep. 2022 Jul;24(7):889-904. doi: 10.1007/s11912-021-01163-2. Epub 2022 Mar 26. Curr Oncol Rep. 2022. PMID: 35347591 Review.
-
Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers.Int J Mol Sci. 2022 Jul 16;23(14):7843. doi: 10.3390/ijms23147843. Int J Mol Sci. 2022. PMID: 35887191 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous